血必净治疗重症肺炎的效果观察及对炎症因子和氧化、抗氧化因子的影响

Observation of effect by Xuebijing in the treatment of severe pneumonia and its influence on inflammatory factor, oxidant factor and antioxidant factor

目的探讨血必净对重症肺炎患者的效果及对炎症因子和氧化、抗氧化因子产生的影响。方法 60例重症肺炎患者,随机分为常规治疗组和血必净干预组,各30例。常规治疗组给予常规治疗,血必净干预组在常规治疗基础上给予血必净注射液治疗。比较两组患者临床疗效、28 d死亡率、肺炎严重度指数(PSI)、血清炎性因子和氧化、抗氧化因子水平。结果治疗后,血必净干预组总有效率为90.0%,显著高于常规治疗组的66.7%,28 d死亡率为16.7%,低于常规治疗组的43.3%(P<0.05)。治疗后血必净干预组PSI评分、白介素6(IL-6)、肿瘤坏死因子-α(TNF-α)、丙二醛(MDA)水平较常规治疗组下降更为显著,超氧化物歧化酶(SOD)水平较常规治疗组上升显著(P<0.05)。结论血必净注射液可以改善重症肺炎患者的预后,而通过调节血清中促炎因子以及氧化和抗氧化因子水平可能是其途径之一。

Objective To investigate effect by Xuebijing in the treatment of severe pneumonia and its influence on inflammatory factor, oxidant factor and antioxidant factor. Methods A total of 60 patients with severe pneumonia were randomly divided into conventional treatment group and Xuebijing intervention group, with 30 cases in each group. The conventional treatment group received conventional therapy, and the Xuebijing intervention group received additional Xuebijing injection for treatment. Comparison was made on clinical effects, 28 d mortality rate, pneumonia severity index（PSI）, serum inflammatory factor, oxidant factor and antioxidant factor levels between the two groups. Results After treatment, the Xuebijing intervention group had total effective rate as 90.0%, which was obviously higher than 66.7% of the conventional treatment group, and its 28 d mortality rate was lower as 16.7% than 43.3% of the conventional treatment group（P〈0.05）. The Xuebijing intervention group had more obvious decrease of PSI score, interleukin-6（IL-6）, tumor necrosis factor-α（TNF-α） and methane dicarboxylic aldehyde（MDA） levels after treatment than the conventional treatment group, while its superoxide dismutase（SOD） level showed more remarkable increase than the conventional treatment group（P〈0.05）. Conclusion Regulation of serum inflammatory factor, oxidant factor and antioxidant factor levels by Xuebijing injection may enable its improvement of prognosis in severe pneumonia patients.